HomeGeneticsConditionComplete plasminogen activator inhibitor 1 deficiency
Back to Condition
Complete plasminogen activator inhibitor 1 deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Complete plasminogen activator inhibitor 1 deficiency

Complete plasminogen activator inhibitor 1 (PAI-1) deficiency is a rare bleeding disorder that prevents blood clots from remaining stable, leading to excessive and prolonged bleeding.

Overview

In individuals with complete PAI-1 deficiency, blood clots dissolve prematurely, causing excessive bleeding after injuries or medical procedures. Symptoms include prolonged nosebleeds, easy bruising, and significant bleeding into joints or soft tissues. Internal bleeding, such as intracranial hemorrhage, can be life-threatening. Females may experience heavy menstrual bleeding (menorrhagia) and complications during pregnancy and childbirth.

Long-term Complications

Beyond bleeding issues, some affected individuals develop scar tissue in the heart, known as cardiac fibrosis, which can lead to heart failure.

Causes

The disorder is caused by mutations in the SERPINE1 gene, which provides instructions for making the PAI-1 protein. Under normal conditions, PAI-1 helps stabilize blood clots by inhibiting proteins that dissolve them (fibrinolysis). Mutations in the SERPINE1 gene result in a nonfunctional or unstable PAI-1 protein. Without this protein, blood clots are broken down too quickly, leading to the bleeding tendencies characteristic of the disorder.

Inheritance

This condition is inherited in an autosomal recessive pattern. This means both copies of the gene in each cell must have mutations for the disorder to occur. Parents of an affected individual each carry one copy of the mutated gene but typically do not exhibit signs or symptoms of the condition.

Frequently Asked Questions

Diagnosis is confirmed by measuring PAI‑1 antigen levels and functional activity in the blood, followed by genetic testing for mutations in the SERPINE1 gene. No special fasting is required, but you should stop taking NSAIDs, aspirin, or any anticoagulants at least 48 hours before the blood draw, as these can interfere with fibrinolysis assays.
Long‑term prophylaxis with oral tranexamic acid or epsilon‑aminocaproic acid can reduce bleeding frequency, especially during periods of high risk (e.g., menstruation, dental work). Regular monitoring of bleeding episodes, avoiding high‑impact activities, and maintaining a cardiac evaluation for potential fibrosis are also recommended. Discuss a personalized plan with your hematologist.===
PAI‑1 deficiency typically presents with bleeding that is unusually long after minor injuries, especially mucosal bleeding such as nosebleeds or heavy menstrual bleeding, while standard clotting tests (PT, aPTT) remain normal. If you notice that your blood stops clotting quickly but your platelet count and clotting times are within normal ranges, this pattern should prompt a discussion with your clinician about a possible PAI‑1 deficiency.
Before any invasive procedure, discuss with your dentist or surgeon the use of antifibrinolytic agents such as tranexamic acid (oral or IV) and topical hemostatic agents. Ensure that local pressure can be applied, consider suturing of mucosal wounds, and avoid NSAIDs post‑operatively. Having a written bleeding plan and carrying tranexamic acid tablets can also help manage unexpected bleeding.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss